Following the results presented at #SABCS23, the PREFERABLE-EFFECT trial is now out in @JCO_ASCO
Exercise for patients with metastatic #breastcancer ⬆️quality of life, ⬇️costs, and is cost-effective🏋🏼♀️🏃🏼♀️➡️
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
The highly awaited Breast Cancer trials with positive results - Paolo Tarantino
@ptarantinomd.bsky.social
@sabcs.bsky.social
oncodaily.com/blog/208123
#BreastOncology #Cancer #ESMO23 #FightAgainstCancer #OncoDaily #Oncology #SABCS23 #Medicine #Health
One year ago, on a sunny afternoon before the last session of #SABCS23, I stood on this balcony chatting with patient and advocate Gwen Manchion, who was stolen by MBC in the interim. This is why we do what we do.
#SABCS23 late breaking abstract to FDA approval: #Inavolisib based off #INAVO120 we 🗣️ design, findings, and AEs/management w/ Dr. Komal Jhaveri!
Full Discussion:
- Oncbrothers.com/inavo120
- Also on the “Oncology Brothers” podcast
#OncSky #MedSky #bcsm #BreastCancer #SABCS24
I guess everyone is leaving #SABCS23 before the crack of dawn - haven’t seen this long a TSA pre ✅ line in forever
I love @LesleyKailani who cuts to the chase when asked about the toxicities in the inavolisib+palbo+fulvestrant triplet which showed pretty impressive efficacy but a high incidence of multiple toxicities: “these side effects suck” #SABCS23
Great to have @oesterreichs at tonight’s @abreastcancer “Hot Topics” and the see her in a dress!!!! 😆 #SABCS23
Thank you Dr @stolaney1 for ensuring that we all were able to learn from the incredible #advocate @LesleyKailani during the #SABCS23 view from the trenches session.
There’s something to be said for watching #SABCS23 early morning sessions from bed. Wish I’d figured this out sooner! I’ll walk over to the convention center when the sun is up in California. #ScienceInPajamas #SelfCare
Great group of coauthors at our @AdvocateCollab poster on quality of life issues important to the people actually diagnosed with or living with cancer. #SABCS23
Love it when a pharmaceutical @napopharma company and its CEO listen to people with cancer, to learn about what is important to us in terms of quality of life and supportive care #MakeCancerLessShitty #SABCS23
What a tribute to the vision of the late @AnnePCDI that @the_rightdose is featured at this #SABCS23 satellite symposium. Dr @hoperugo is on the medical advisory board and speaks of how honored she was to participate 🩵💗💚
Happy to listen and learn at this #SABCS23 satellite symposium by @PeerView,
in collaboration with @GRASPtweets @LivingBeyondBC featuring some of my favorite oncologists @ErikaHamilton9 @hoperugo @jhaveri_komal & @PTarantinoMD
Always wonderful to catch up with researchers and oncologists and fellow #advocates at #SABCS23. Come for the science, stay for the hugs. @DrSGraff @StoverLab Chuck Harrell, @drdonsdizon
How to treat? What is the result of reevaluation for ER and HER2? If ER+ what about a CDK4/6i?
Given high TMB she was given paclitaxel and pembrolizumab with response. Bottom line: sometimes you have to look for zebras when you hear hoofbeats. #SABCS23.
Next case: history of early bc, now with pancreatic mass. Is it pancreatic cancer? Later lung, liver and bone mets appear after treatment for presumptive pancreatic cancer and mixed response. Liver bc c/w a neuroendocrine tumor NOT associated with pancreatic cancer . #SABCS23
She was put on BRAF directed therapy + fulvestrant with a good response! And what about hitting that BRCA2 somatic mutation with olaparib? Could be a good choice with next progression. #SABCS23 molecular targeting for the win!
Interestingly, she had somatic BRCA2 mutation and BRAFv600. BRAF, while rare, can confer endocrine resistance, and BRCA2 might lead to CDK4/6i resistance. Can we target BRAFv600e? #SABCS23
Molecular tumor board or how can we use genomics/biomarkers to make treatment decisions. Path shows lobular disease, rapid progression on 1st line therapy. What to do? Does she have PIK3CA? ESR1? But with rapid progression on ET +CDK4/6 elacestrant less effective. #SABCS23
So happy to see the interest in @lyndaweatherby Victoria Goldberg et al’s poster on postpartum breast cancer. #SABCS23
Bar chart of pCR rates (ypT0 ypN0), by chemotherapy arm (weekly vs day 1,8 q22) and primary mutation definition (BRCA1 and BRCA2) for different subgroups.
Germline mutation status of BRCA1/2 as biomarker: Higher pCR rates observed in mutations carriers in all arms. Mutation carriers and non-carriers benefitted most from weekly nab-paclitaxel.
Analysis from GeparX-trial presented at #SABCS23 #breastcancer
I love @DrSGraff, moderator of this #SABCS23 session, who is an incredible oncologist, educator, champion for patients/advocates, and all around awesome human being like, for giving the patient (@AMJohnston1315 ) the last word of this session
Some suggestions for our care teams, including that (gasp!) we have lives outside of cancer and simple things like scheduling visits/scans/etc should be done WITH us and not TO us. #SABCS23
Abigail believes our oncologist should ask these 3 questions: what are your priorities/what’s important to you; how you want to make decisions; how do you learn (auditory, visual, etc). Without these fundamentals, can it really be shared decision making? #SABCS23
So happy to see #advocate @AMJohnston1315 actually invited to give a presentation!!! Every treatment decision comes with calculations about efficacy, toxicity, financial and time toxicities, impact on family, etc, etc, etc. #SABCS23
Dr Erica Stringer-Reasor talks about sacituzumab govetecan (Trodelvy) currently approved in ER+HER2- and mTNBC. This is an ADC targeted to TROP2, although it was effective even in TROP2 negative (but most effective in those with TROP2 over expression). #SABCS23
Combos with oral SERDs (and CERANs and the rest of the alphabet soup) are in the works. I’m excited about the possibility of these (super happy so far with my combo of investigational palazestrant (SERD and CERAN) with ribociclib) #SABCS23
And we shouldn’t forget about older drugs, like everolimus, where everolimus + fulvestrant was better than fulvestrant alone (again the whole monotherapy after progression on a combo issue). #SABCS23
Can we switch from 1 CDK4/6i to another? In the case of switching to ribociclib, the answer is yes. #SABCS23
